Deal Snapshot
Irish Biotech Inflazome Agrees to Roche Buyout
Monday 21 September 2020

Ireland-based biotechnology company Inflazome has closed a share purchase agreement with Swiss healthcare company Roche (SIX: RO) (OTCQX: RHHBY) in which Inflazome's shareholders received an upfront payment of EUR 380m (USD 447.22m), and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones, the company said.

Inflazome was founded in 2016 by medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O'Neill (Trinity College Dublin, Ireland).

Date Published: 21/09/2020